share_log

Lifecome Biochemistry Co.,Ltd.'s (SZSE:002868) Last Week's 9.1% Decline Must Have Disappointed Individual Investors Who Have a Significant Stake

Lifecome Biochemistry Co.,Ltd.'s (SZSE:002868) Last Week's 9.1% Decline Must Have Disappointed Individual Investors Who Have a Significant Stake

Lifecome 生物化學公司, Ltd. 's(SZSE: 002868)上週9.1%的跌幅一定讓持有大量股份的個人投資者失望
Simply Wall St ·  2023/02/22 22:52

Key Insights

關鍵見解

  • The considerable ownership by individual investors in Lifecome BiochemistryLtd indicates that they collectively have a greater say in management and business strategy
  • 47% of the business is held by the top 13 shareholders
  • Insider ownership in Lifecome BiochemistryLtd is 35%
  • 個人投資者對Lifecome BioChemistryLtd的大量所有權表明,他們在管理和業務戰略中集體擁有更大的發言權
  • 47% 的業務由前 13 名股東持有
  • Lifecome BioChemistryLtd 的內部所有權

If you want to know who really controls Lifecome Biochemistry Co.,Ltd. (SZSE:002868), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 53% to be precise, is individual investors. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

如果你想知道誰真正控制了Lifecome Biecome Co.,Ltd.(深圳證券交易所代碼:002868),那麼你得看看其股票登記處的構成。持有公司股份最多的集團,確切地說約爲53%,是個人投資者。也就是說,如果股票上漲,該集團將受益最大(如果出現下跌,則損失最大)。

While insiders, who own 35% shares weren't spared from last week's CN¥753m market cap drop, individual investors as a group suffered the maximum losses

儘管擁有35%股票的內部人士未能倖免於上週7.53億元人民幣市值的下跌,但個人投資者作爲一個羣體遭受的損失最大

In the chart below, we zoom in on the different ownership groups of Lifecome BiochemistryLtd.

在下圖中,我們放大了Lifecome BioChemistryLtd的不同所有權類別。

View our latest analysis for Lifecome BiochemistryLtd

查看我們對 Lifecome BioChemistryLtd 的最新

ownership-breakdown
SZSE:002868 Ownership Breakdown February 23rd 2023
深交所:002868 所有權明細 2023 年 2 月 23 日

What Does The Lack Of Institutional Ownership Tell Us About Lifecome BiochemistryLtd?

關於Lifecome BioChemistryLtd,缺乏機構所有權告訴我們甚麼?

Small companies that are not very actively traded often lack institutional investors, but it's less common to see large companies without them.

交易不太活躍的小公司通常缺少機構投資者,但是沒有機構投資者的大公司並不常見。

There are many reasons why a company might not have any institutions on the share registry. It may be hard for institutions to buy large amounts of shares, if liquidity (the amount of shares traded each day) is low. If the company has not needed to raise capital, institutions might lack the opportunity to build a position. Alternatively, there might be something about the company that has kept institutional investors away. Institutional investors may not find the historic growth of the business impressive, or there might be other factors at play. You can see the past revenue performance of Lifecome BiochemistryLtd, for yourself, below.

公司在股票登記處可能沒有任何機構的原因有很多。如果流動性(每天交易的股票數量)很低,機構可能很難購買大量股票。如果公司不需要籌集資金,機構可能缺乏建立職位的機會。或者,該公司的某些方面可能使機構投資者望而卻步。機構投資者可能不會發現該業務的歷史增長令人印象深刻,或者可能還有其他因素在起作用。你可以在下面親眼看到Lifecome BioChemistryLtd過去的收入表現。

earnings-and-revenue-growth
SZSE:002868 Earnings and Revenue Growth February 23rd 2023
深交所:002868 2023 年 2 月 23 日收益和收入增長

Hedge funds don't have many shares in Lifecome BiochemistryLtd. Our data shows that Tan Ping Lai is the largest shareholder with 31% of shares outstanding. In comparison, the second and third largest shareholders hold about 7.2% and 5.0% of the stock. Additionally, the company's CEO Tanping Lai directly holds 1.0% of the total shares outstanding.

對沖基金在Lifecome BioChemistryLtd的股份不多。我們的數據顯示,陳平來是最大的股東,已發行股份的31%。相比之下,第二和第三大股東持有約7.2%和5.0%的股份。此外,該公司首席執行官賴坦平直接持有已發行股份總額的1.0%。

On studying our ownership data, we found that 13 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.

在研究我們的所有權數據時,我們發現13位頂級股東共同擁有的股份不到50%,這意味着沒有一個人擁有多數股權。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.

雖然研究公司的機構所有權可以爲您的研究增加價值,但研究分析師的建議以更深入地瞭解股票的預期表現也是一種好做法。我們的信息表明,分析師對該股沒有任何報道,因此可能鮮爲人知。

Insider Ownership Of Lifecome BiochemistryLtd

Lifecome 生物化學有限公司的內部所有權

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

不同國家對內部人士的定義可能略有不同,但董事會成員始終算在內。管理層最終對董事會負責。但是,經理成爲執行委員會成員的情況並不少見,尤其是當他們是創始人或首席執行官時。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常認爲內部所有權是一件好事。但是,在某些情況下,這使其他股東更難追究董事會對決策的責任。

Our information suggests that insiders maintain a significant holding in Lifecome Biochemistry Co.,Ltd.. It has a market capitalization of just CN¥7.6b, and insiders have CN¥2.7b worth of shares in their own names. That's quite significant. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.

我們的信息表明,內部人士持有Lifecome生物化學公司的大量股份。,有限公司。。它的市值僅爲76億元人民幣,內部人士以自己的名義持有價值27億元的股票。這非常重要。大多數人會說,這表明了與股東的一致性,尤其是在如此規模的公司中。你可以點擊這裏查看那些內部人士是否在買入或賣出。

General Public Ownership

一般公有制

The general public, who are usually individual investors, hold a substantial 53% stake in Lifecome BiochemistryLtd, suggesting it is a fairly popular stock. This level of ownership gives investors from the wider public some power to sway key policy decisions such as board composition, executive compensation, and the dividend payout ratio.

公衆通常是個人投資者,持有Lifecome BioChemistryLtd的53%的大量股份,這表明這是一隻相當受歡迎的股票。這種所有權水平使來自廣大公衆的投資者有一些權力,可以影響董事會組成、高管薪酬和股息支付率等關鍵政策決策。

Private Company Ownership

私人公司所有權

Our data indicates that Private Companies hold 12%, of the company's shares. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

我們的數據表明,私營公司持有公司12%的股份。僅憑這一事實很難得出任何結論,因此值得研究誰擁有這些私營公司。有時,內部人士或其他關聯方通過一家獨立的私營公司對上市公司的股票感興趣。

Next Steps:

後續步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Lifecome BiochemistryLtd , and understanding them should be part of your investment process.

我覺得看看究竟是誰擁有一家公司非常有趣。但是,要真正獲得見解,我們也需要考慮其他信息。例如,以永遠存在的投資風險幽靈爲例。 我們已經確定了 2 個警告信號 有了Lifecome BioChemistryLtd,瞭解它們應該是你投資過程的一部分。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然, 你可能會在其他地方找到一筆不錯的投資。 所以來看看這個 免費的 有趣的公司名單。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂? 取得聯繫 直接和我們聯繫。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是一般性的。 我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章無意提供財務建議。 它不構成買入或賣出任何股票的建議,也沒有考慮您的目標或財務狀況。我們的目標是爲您提供由基本面數據驅動的長期重點分析。請注意,我們的分析可能未將最新的價格敏感型公司公告或定性材料考慮在內。簡而言之,華爾街對上述任何股票都沒有頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論